-
Pembrolizumab, sold
under the
brand name Keytruda, is a
humanized antibody, more
specifically a PD-1 Inhibitor, used in
cancer immunotherapy that treats...
- Favezelimab/
pembrolizumab is a fixed-dose
combination of two
monoclonal antibodies developed by
Merck to
treat various cancers. Timmerman, John; Lavie...
- As
adjuvant therapy, mRNA-4157
monotherapy and in
combination with
pembrolizumab have been
investigated in
patients with
resected solid tumors (melanoma...
- system.
Atezolizumab is an anti PD-L1
monoclonal antibody.
Nivolumab and
Pembrolizumab are anti PD-1
monoclonal antibodies.
Ipilimumab is a
monoclonal antibody...
-
immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS.
Pembrolizumab (Keytruda,
formerly MK-3475 and lambrolizumab) was
developed by Merck...
-
treatment options.
Pembrolizumab monotherapy is an
appealing approach for
these patients, with
median OS of 30
months with
pembrolizumab single agent compared...
-
checkpoint inhibitors include antibodies such as ipilimumab, nivolumab, and
pembrolizumab.
Dendritic cell
therapy provokes anti-tumor
responses by
causing dendritic...
- It is
being tested by
itself and in a fixed-dose
combination with
pembrolizumab. Garralda, E.; ****ri, A.; Lakhani, N. J.; Patnaik, A.; Lou, Y.; Im...
-
response rate with
median progression free
survival of 10.5
months Pembrolizumab: 12%
objective response rate with
median progression free
survival of...
- quality-****ured
biosimilars Afatinib and
gefitinib are
alternatives Pembrolizumab is an alternative,
including quality-****ured
biosimilars Enzalutamide...
